Use of SMOF lipid emulsion in very preterm infants does not affect the incidence of bronchopulmonary dysplasia–free survival.

MLA

Ndiaye, Aissatou B. K. T., et al. “Use of SMOF Lipid Emulsion in Very Preterm Infants Does Not Affect the Incidence of Bronchopulmonary Dysplasia–free Survival.” JPEN Journal of Parenteral & Enteral Nutrition, vol. 46, no. 8, Nov. 2022, pp. 1892–902. EBSCOhost, https://doi.org/10.1002/jpen.2380.

APA

Ndiaye, A. B. K. T., Mohamed, I., Pronovost, E., Angoa, G., Piedboeuf, B., Lemyre, B., Afifi, J., Qureshi, M., Sériès, T., Guillot, M., Simonyan, D., Yusuf, K., Lavoie, P. M., Fraser, W. D., Mâsse, B., Nuyt, A. M., Lacaze, M. T., & Marc, I. (2022). Use of SMOF lipid emulsion in very preterm infants does not affect the incidence of bronchopulmonary dysplasia–free survival. JPEN Journal of Parenteral & Enteral Nutrition, 46(8), 1892–1902. https://doi.org/10.1002/jpen.2380

Chicago

Ndiaye, Aissatou B.K.T., Ibrahim Mohamed, Etienne Pronovost, Georgina Angoa, Bruno Piedboeuf, Brigitte Lemyre, Jehier Afifi, et al. 2022. “Use of SMOF Lipid Emulsion in Very Preterm Infants Does Not Affect the Incidence of Bronchopulmonary Dysplasia–free Survival.” JPEN Journal of Parenteral & Enteral Nutrition 46 (8): 1892–1902. doi:10.1002/jpen.2380.